Zealand Pharma ROA - Return on Assets 2017-2024 | ZLDPF

Zealand Pharma return on assets for the quarter ending June 30, 2024 was -15.74.

  • Zealand Pharma average return on assets for 2023 was -58.97, a 14.56% decline from 2022.
  • Zealand Pharma average return on assets for 2022 was -69.02, a 29.23% decline from 2021.
  • Zealand Pharma average return on assets for 2021 was -53.41, a 39.56% increase from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

Zealand Pharma ROA - Return on Assets 2017-2024 | ZLDPF

  • Zealand Pharma average return on assets for 2023 was -58.97, a 14.56% decline from 2022.
  • Zealand Pharma average return on assets for 2022 was -69.02, a 29.23% decline from 2021.
  • Zealand Pharma average return on assets for 2021 was -53.41, a 39.56% increase from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.8B
Vertex Pharmaceuticals (VRTX)$117.5B
Regeneron Pharmaceuticals (REGN)$111.6B
Bristol Myers Squibb (BMY)$109.4B
Gilead Sciences (GILD)$105.3B
CSL (CSLLY)$95.7B
GSK (GSK)$80.5B
Alnylam Pharmaceuticals (ALNY)$34.4B
Argenex SE (ARGX)$31.7B
BioNTech SE (BNTX)$29.2B
Biogen (BIIB)$27B
BeiGene (BGNE)$23.9B
Moderna (MRNA)$23.1B
Illumina (ILMN)$22.5B
Genmab (GMAB)$15.5B
BioMarin Pharmaceutical (BMRN)$13.2B
Incyte (INCY)$13B
Exact Sciences (EXAS)$12.6B
Vaxcyte (PCVX)$12.4B
Insmed (INSM)$12.4B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.5B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$8.9B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$8.3B
Revolution Medicines (RVMD)$7.9B
Intra-Cellular Therapies (ITCI)$7.7B
Repligen (RGEN)$7.7B